{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(1)"],"submitter":["Aziz NA"],"pubmed_abstract":["To estimate the seroprevalence and temporal course of SARS-CoV-2 neutralizing antibodies, we embedded a multi-tiered seroprevalence survey within an ongoing community-based cohort study in Bonn, Germany. We first assessed anti-SARS-CoV-2 immunoglobulin G levels with an immunoassay, followed by confirmatory testing of borderline and positive test results with a recombinant spike-based immunofluorescence assay and a plaque reduction neutralization test (PRNT). Those with a borderline or positive immunoassay result were retested after 4 to 5 months. At baseline, 4771 persons participated (88% response rate). Between April 24<sup>th</sup> and June 30<sup>th</sup>, 2020, seroprevalence was 0.97% (95% CI: 0.72-1.30) by immunoassay and 0.36% (95% CI: 0.21-0.61) when considering only those with two additional positive confirmatory tests. Importantly, about 20% of PRNT+ individuals lost their neutralizing antibodies within five months. Here, we show that neutralizing antibodies are detectable in only one third of those with a positive immunoassay result, and wane relatively quickly."],"journal":["Nature communications"],"pagination":["2117"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8035181"],"repository":["biostudies-literature"],"pubmed_title":["Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany."],"pmcid":["PMC8035181"],"pubmed_authors":["Schmidt ML","Muller MA","de Vries FM","Breteler MMB","Schmandke A","Corman VM","Drosten C","Aziz NA","Schmidt TH","Echterhoff AKC","Richter A"],"additional_accession":[]},"is_claimable":false,"name":"Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany.","description":"To estimate the seroprevalence and temporal course of SARS-CoV-2 neutralizing antibodies, we embedded a multi-tiered seroprevalence survey within an ongoing community-based cohort study in Bonn, Germany. We first assessed anti-SARS-CoV-2 immunoglobulin G levels with an immunoassay, followed by confirmatory testing of borderline and positive test results with a recombinant spike-based immunofluorescence assay and a plaque reduction neutralization test (PRNT). Those with a borderline or positive immunoassay result were retested after 4 to 5 months. At baseline, 4771 persons participated (88% response rate). Between April 24<sup>th</sup> and June 30<sup>th</sup>, 2020, seroprevalence was 0.97% (95% CI: 0.72-1.30) by immunoassay and 0.36% (95% CI: 0.21-0.61) when considering only those with two additional positive confirmatory tests. Importantly, about 20% of PRNT+ individuals lost their neutralizing antibodies within five months. Here, we show that neutralizing antibodies are detectable in only one third of those with a positive immunoassay result, and wane relatively quickly.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Apr","modification":"2022-02-09T18:02:04.874Z","creation":"2022-02-09T18:02:04.874Z"},"accession":"S-EPMC8035181","cross_references":{"pubmed":["33837204"],"doi":["10.1038/s41467-021-22351-5"]}}